Purpose: Denture survival, or the time between the date of a denture's insertion and the date of its renewal for any clinical reason, was assessed in this retrospective study on 353 complete dentures. The procedures required to prolong the useful time of the study sample-relines, repair of denture base fractures, or replacement of lost artificial teeth-were also evaluated.
Materials And Methods: All dentures were examined by the authors and were constructed according to a standardized protocol by full-time staff members of the Department of Prosthodontics, Regensburg University Medical Center, between 1984 and 2009. Two subgroups were assigned: 94 patients had one complete denture in each arch (group 1), while 165 patients had one complete denture in either the mandible or the maxilla (group 2).
Results: In group 1, the median (75th, 90th percentile) survival time of dentures was 15.8 years in the mandible (15.7, 7.0; 95% confidence interval [CI]: 15.5 to 16.1) and 19.4 years in the maxilla (15.8, 8.7; 95% CI: 14.0 to 24.7). Reline procedures were required most frequently in the maxilla, while 5-year event-free rates were 69.7% for the maxilla and 80.5% for the mandible. Denture base fractures were reported in 5.8% of patients in group 1 and tended to occur more frequently (median: 15.2%) if patients had only one denture (group 2, n = 25 [maxilla: n = 23, mandible: n = 2]). Loss of artificial teeth was a rare complication and found in only 5.8% of patients in group 1 and 10.9% of patients in group 2. During the first 5 years of service, more than 95% of patients in group 1 and 90% of patients in group 2 were "event free" with regard to loss of artificial teeth.
Conclusions: Long-term functional service of complete dentures requires a high number of maintenance procedures, and there is a greater need for interventions in patients wearing only one complete denture (group 2).
Download full-text PDF |
Source |
---|
Alzheimers Dement
December 2024
Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.
Background: The DL-3-n-butylphthalide (NBP), a multi-target neuroprotective drug, improving cognitive impairment in patient with vascular cognitive impairment has been confirmed. The efficacy of NBP in patients with cognitive impairment due to Alzheimer's disease (AD) remains unknown. This study aimed to evaluate the efficacy and safety of NBP in patients with mild cognitive impairment (MCI) due to AD though a clinical randomized controlled trail.
View Article and Find Full Text PDFBackground: Focused ultrasound (FUS)-induced blood-brain barrier opening (BBBO) is a technique for safely, non-invasively, and transiently opening the blood brain barrier in a targeted area of the brain. Pre-clinical and clinical studies have shown that FUS is capable of decreasing amyloid plaque load and stimulating neurogenesis in Alzheimer's Disease (AD) models, in addition to being safe for use in human patients. However, the effect of FUS-BBBO on neurons has not yet been characterized, despite its crucial role in cognition and regulating brain function.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Centre for Addiction and Mental Health, Toronto, ON, Canada.
Background: Dysregulated GABA/somatostatin (SST) signaling has been implicated in psychiatric and neurodegenerative disorders. The inhibition of excitatory neurons by SST+ interneurons, particularly through α5-containing GABAA receptors (α5-GABAAR), plays a crucial role in mitigating cognitive functions. Previous research demonstrated that an α5-positive allosteric modulator (α5-PAM) mitigates working memory deficits and reverses neuronal atrophy in aged mice.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Imperial College London, London, United Kingdom; Division of Neurology, Department of Brain Sciences, Imperial College London, United Kingdom, London, London, United Kingdom.
Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue licensed for the treatment of type 2 diabetes mellitus (T2DM). Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells.
Method: This is a multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild to moderate Alzheimer's dementia, conducted at several centres in the UK.
Alzheimers Dement
December 2024
NYU Grossman School of Medicine, New York, NY, USA; NYU, New York City, NY, USA.
Background: Astrocytes, a major glial cell in the central nervous system (CNS), can become reactive in response to inflammation or injury, and release toxic factors that kill specific subtypes of neurons. Over the past several decades, many groups report that reactive astrocytes are present in the brains of patients with Alzheimer's disease, as well as several other neurodegenerative diseases. In addition, reactive astrocyte sub-types most associated with these diseases are now reported to be present during CNS cancers of several types.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!